Glaucoma Combination Therapy with Sulfonamide and Adjunct Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, particularly in relation to intraocular pressure, often involve single-drug therapies that may not provide optimal lowering effects, and there is a lack of reported combinations involving isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl) aminomethyl}pyridin-2-ylamino) acetate with other therapeutic agents for enhanced efficacy.
Innovation Solution
Combining isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl) aminomethyl}pyridin-2-ylamino) acetate with other preventive or therapeutic drugs such as nonselective sympathomimetic drugs, α2-receptor agonists, β-receptor antagonists, carbonic anhydrase inhibitors, prostaglandins, or Rho-kinase inhibitors to enhance intraocular pressure lowering effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single-agent therapy is used for glaucoma, then treatment simplicity is maintained, but intraocular pressure lowering effect is insufficient
Solution Approach 1:
The patent combines isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl) aminomethyl}pyridin-2-ylamino) acetate with other glaucoma therapeutic agents into a single combination therapy regimen. This merging of multiple single-agent therapies into one coordinated treatment approach achieves enhanced intraocular pressure lowering effects while maintaining treatment simplicity through unified administration protocols
2Reliability
If combination therapy is used for glaucoma, then intraocular pressure lowering effect is enhanced, but treatment complexity increases
Solution Approach 1:
The patent segments the combination therapy into clearly defined components with specific dosing schedules and administration timing. By dividing the complex regimen into manageable segments (specific doses of each agent at specified intervals), the therapy maintains enhanced efficacy while improving ease of operation through structured, organized administration protocols
Data Source
AI summary
A preventive or therapeutic agent for glaucoma or ocular hypertension includes a combination of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl) aminomethyl}pyridin-2-ylamino)acetate with one or more other preventive or therapeutic drugs for glaucoma or ocular hypertension, with the proviso that tafluprost is excluded.